July 12 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES REPORTS SECOND QUARTER 2023 FINANCIAL
RESULTS
AND BUSINESS UPDATES
* THERATECHNOLOGIES INC - FY2023 REVENUE GUIDANCE RECAST TO
FALL
WITHIN $82 MILLION AND $87 MILLION
* THERATECHNOLOGIES INC - Q2 2023 CONSOLIDATED REVENUE WERE
AFFECTED BY SPECIALTY PHARMACY INVENTORY ADJUSTMENTS, AND CAME
IN AT $17.5 MILLION
* THERATECHNOLOGIES - THERE IS MATERIAL UNCERTAINTY RELATED
TO
EVENTS/CONDITIONS THAT CAST SUBSTANTIAL DOUBT ABOUT ABILITY TO
CONTINUE AS GOING CONCERN
* THERATECHNOLOGIES INC - INITIATED REORGANIZATION OF
RESEARCH AND
DEVELOPMENT ACTIVITIES, EXPECTED TO RESULT IN ANNUALIZED SAVINGS
OF AT LEAST $5.5 MILLION FOR FY 2024 & BEYOND
* THERATECHNOLOGIES INC - EXPECTS TO RECORD A CHARGE OF $1.5
MILLION TO COVER ANTICIPATED SEVERANCE AND OTHER COSTS
Source text for Eikon: ID:nGNX5gbG1q
Further company coverage: TH.TO